Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonapegsomatropin Extension Study in Adults With Growth Hormone Deficiency
NCT05171855Phase 3Completed
- Sponsor
- Ascendis Pharma
- Start
- Dec 2021
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Prodrugs/Conditional Activator Small Molecules
- Countries
- 21
01
Overview
Phase 3, open-label trial of lonapegsomatropin in growth hormone deficiency (GHD) (3 arms), sponsored by Ascendis Pharma. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAE Leading to Study Discontinuation at 52 weeks. Started Dec 2021; status: completed.
02
Drugs
lonapegsomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT05171855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171855.